It will allow swift transport links to GSK's main R&D campus in Stevenage – where the company is also developing a new bioscience cluster – and will also be close to its artificial ...

Based near GSK’s research base in Stevenage, KaNDy was spun out of NeRRe Therapeutics in 2017, itself a spin-off from the big UK pharma following its decision to withdraw from neuroscience R&D ...

Deborah Waterhouse, CEO, ViiV Healthcare and President, Global Health, GSK, said: “At ViiV Healthcare we believe that everyone, no matter where they live, should have the freedom to be their authentic ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

As of November 08, 2024, GSK plc had a $73.1 billion market capitalization, putting it in the 96th percentile of companies in the Pharmaceuticals industry. Currently, GSK plc’s price-earnings ratio is ...

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.